Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Karuna Therapeutics (NASDAQ:KRTX) will present data from the EMERGENT-1, EMERGENT-2, and EMERGENT-3 trials evaluating KarXT in schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting from May 30 to June 2, 2023.
May 22, 2023 | 10:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Karuna Therapeutics will present data from the EMERGENT trials evaluating KarXT in schizophrenia at the ASCP Annual Meeting, potentially impacting the stock price.
The presentation of data from the EMERGENT trials at the ASCP Annual Meeting could have a positive impact on KRTX's stock price, as it may indicate progress in the development of KarXT for schizophrenia treatment. Positive results could attract investor interest and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100